



OPEN ACCESS

EDITED AND REVIEWED BY
Nathalie K. Zgheib,
American University of Beirut, Lebanon

*CORRESPONDENCE
Luis Abel Quiñones,
✉ lquinone@uchile.cl

RECEIVED 05 March 2025
ACCEPTED 13 March 2025
PUBLISHED 31 March 2025

CITATION

Roco A, Nieto E, Suárez M, Rojo M, Bertoglia MP, Verón G, Tamayo F, Arredondo A, Cruz D, Muñoz J, Bravo G, Salas P, Mejías F, Godoy G, Véliz P and Quiñones LA (2025) Corrigendum: A pharmacogenetically-guided acenocoumarol dosing algorithm for Chilean patients: a discovery cohort study. *Front. Pharmacol.* 16:1588440. doi: 10.3389/fphar.2025.1588440

COPYRIGHT

© 2025 Roco, Nieto, Suárez, Rojo, Bertoglia, Verón, Tamayo, Arredondo, Cruz, Muñoz, Bravo, Salas, Mejías, Godoy, Véliz and Quiñones. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Corrigendum: A pharmacogenetically-guided acenocoumarol dosing algorithm for Chilean patients: a discovery cohort study

Angela Roco^{1,2,3}, Elena Nieto⁴, Marcelo Suárez¹, Mario Rojo^{1,5}, Maria Paz Bertoglia⁶, Gabriel Verón¹, Francisca Tamayo¹, Annabella Arredondo⁷, Daniela Cruz⁴, Jessica Muñoz⁴, Gabriela Bravo⁸, Patricio Salas⁹, Fanny Mejías¹⁰, Gerald Godoy¹⁰, Paulo Véliz¹⁰ and Luis Abel Quiñones^{1,5*}

¹Laboratory of Chemical Carcinogenesis and Pharmacogenetics, Department of Basic and Clinical Oncology, Faculty of Medicine, University of Chile, Santiago, Chile, ²Escuela de Bioquímica Facultad de Ciencias de la Vida, Universidad Andrés Bello, Santiago, Chile, ³Western Metropolitan Health Service, Santiago, Chile, ⁴San Juan de Dios Hospital, Santiago, Chile, ⁵Latin American Network for Implementation and Validation of Clinical Pharmacogenomics Guidelines (RELIVAF-CYTED), Madrid, Spain, ⁶Institute of Population Health, University of Chile, Santiago, Chile, ⁷Instituto de Salud Pública, Universidad Andrés Bello, Santiago, Chile, ⁸Curacaví Hospital, Curacaví, Chile, ⁹Dr. Salvador Allende G. Reference Health Center, Santiago, Chile, ¹⁰San José de Melipilla Hospital, Melipilla, Chile

KEYWORDS

acenocoumarol, coumarins, algorithm, pharmacogenetics, pharmacogenomics, anticoagulation

A Corrigendum on A pharmacogenetically-guided acenocoumarol dosing algorithm for Chilean patients: a discovery cohort study

by Roco A, Nieto E, Suárez M, Rojo M, Bertoglia MP, Verón G, Tamayo F, Arredondo A, Cruz D, Muñoz J, Bravo G, Salas P, Mejías F, Godoy G, Véliz P and Quiñones LA (2025). *Front. Pharmacol.* 16:1588440. doi: 10.3389/fphar.2025.1588440


In the published article, there was an error in [Figure 1](#) as published. The patient numbers are listed as 377 --> 377 --> 304, but it should say 377 --> 305 --> 304. The corrected [Figure 1](#) and its caption appear below.

In the published article, there was an error in **Results**, *Algorithm for Acenocoumarol Dosing in the Chilean Population*. In the formula two factors have decimals placed incorrectly. It's a formatting error, but it is significant as it impacts the dose calculations.

The formula previously stated:

“Log WTD = 3.081 + (0.167 × men) - (age × 0.081) - (initial INR × 0.55) + (BMI × 0.013) - (CYP2C9*1/*2 × 0.107) - (CYP2C9*1/*3 × 0.323) - (CYP2C9*3/*3 × 0.746) - (VKORC1 G/A × 0.270) - (VKORC1 A/A × 0.701).”

The corrected formula appears below:



“Log WTD = 3.081 + (0.167 × men) - (age × 0.0081) - (initial INR × 0.055) + (BMI × 0.013) - (CYP2C9*1/*2 × 0.107) - (CYP2C9*1/*3 × 0.323) - (CYP2C9*3/*3 × 0.746) - (VKORC1 G/A × 0.270) - (VKORC1 A/A × 0.701).”

In the published article, there was an error in **Results**, *Genotype Distribution in the Study Population*, paragraph 1.

This sentence previously stated:

“The analysis of the HWE showed that only CYP2C9*3 (rs1057910) is in HWE (chi2 = 4.67). All other SNPs, VKORC1 (rs9923231) (chi2 = 0.09), VKORC1 (rs7294) (chi2 = 0.62), GGCx (rs11676382) (chi2 = 1.2), CYP4F2 (rs2108622) (chi2 = 1.02), ApoE (rs429358) (chi2 = 0.08), ABCB1 (rs1045642) (chi2 = 0.68), and CYP2C9*2 (rs1799853) (chi2 = 2.33), are not in HWE.”

The corrected sentence appears below:

“The analysis of the HWE showed that only CYP2C9*3 (rs1057910) is not in HWE (chi2 = 4.67). All other SNPs, VKORC1(rs9923231) (chi2 = 0.09), VKORC1 (rs7294) (chi2 = 0.62), GGCx (rs11676382) (chi2 = 1.2), CYP4F2 (rs2108622) (chi2 = 1.02), ApoE (rs429358) (chi2 = 0.08), ABCB1 (rs1045642) (chi2 = 0.68), and CYP2C9*2 (rs1799853) (chi2 = 2.33), are in HWE.”

The correspondence email for author Luis Abel Quiñones has been updated in the published article to lquinone@uchile.cl.

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.